A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer
- 31 July 2000
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 29 (1) , 67-73
- https://doi.org/10.1016/s0169-5002(00)00099-4
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II studyLung Cancer, 1998
- Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.Cancer Chemotherapy and Pharmacology, 1997
- Phase II study of weekly gemcitabine in advanced non-small cell lung cancerRespiratory Medicine, 1997
- Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancerAnnals of Oncology, 1997
- Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.Journal of Clinical Oncology, 1997
- Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II studyEuropean Journal Of Cancer, 1996
- Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cAnnals of Oncology, 1994
- Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Clinical and preclinical activity of 2′,2′- difluorodeoxycytidine (gemcitabine)Cancer Treatment Reviews, 1993
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991